|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||0.2291 - 0.2400|
|52 Week Range||0.1340 - 1.2300|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.
TORONTO, ON / ACCESSWIRE / May 10, 2022 / Novamind Inc.(CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, today announced it has been selected to host a clinical trial for the acute treatment of social anxiety disorder (SAD), an understudied and common mental health condition that affects nearly 15 million American adults.
Collaboration with HealCommunity Offers Remote Access to Reimbursable Group Therapy OptionTORONTO, ON / ACCESSWIRE / May 2, 2022 / Novamind Inc.(CSE:NM)(OTCQB:NVMDF)(FSE:HN2) ("Novamind" or the "Company"), a leading mental health company specialized in psychedelic medicine, is pleased to announce its collaboration with virtual health coaching experts, HealCommunity, to provide remote group therapy and behavioral health coaching to Novamind's clients (the "Coaching Program").